A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies

Trial Profile

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Nivolumab (Primary) ; Crizotinib; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CheckMate 370
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 25 Jan 2017 Planned number of patients changed from 1953 to 555.
    • 07 Dec 2016 Trial design presented at the 17th World Conference on Lung Cancer
    • 01 Nov 2016 Trial design published in the Journal of Thoracic Oncology: official publication of the International Association for the Study of Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top